Analysis of electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) - aVenture Research
electroCore
electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Submission backed by clinical data from two clinical studies representing 168 subjects demonstrating quality of life improvements and an approximately 40% reduction in neuropathic pain scores in the active treatment group ROCKAWAY, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc.
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.